Drug intelligence / Profile preview

RB-1916

Development stage: Preclinical
Lead developer: Refuge Biotechnologies
Modality: Cell Therapies, CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies, Gene Addition/Replacement → Gene Therapies

Overview

RB-1916 is a lead intelligent cell therapy candidate developed by Refuge Biotechnologies. It utilizes the company's receptor-dCas platform for precision CRISPR activation and interference to target cancer cells. The drug is being developed for diffuse large B-cell lymphoma and other solid tumors, aiming to create more targeted and potent cell therapies with fewer side effects.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on RB-1916.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RB-1916.

Explore the full profile